伊瓦布拉丁作为对姿势正静性心力衰竭综合征的治疗方法:系统性审查
Chun Shing Kwok1, David Gillespie1, Naeem Ur Rehman Qazi1
1Department of Cardiology, Mid Cheshire Hospital NHS Foundation Trust, Crewe, UK.
Journal of cardiovascular pharmacology
|December 9, 2025
概括
伊瓦布拉丁通过降低心率和改善症状,对治疗姿态正静性心律失常综合征 (POTS) 有望. 然而,证据质量较低,需要进一步的研究来证实其在POTS患者中的有效性和安全性.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 姿势静止性心律失速综合征 (POTS) 是一种影响心率调节的疾病.
- 伊瓦布拉丁是一种非标签药物,被认为用于POTS管理.
研究的目的:
- 系统地审查有关IVABRADINE治疗POTS的现有文献.
- 综合关于伊瓦布拉丁在POTS患者的疗效和安全性的证据.
主要方法:
- 进行了系统的文献审查.
- 包括11项研究,共305名参与者 (2008-2020年).
- 由于研究异质性,数据被叙述性合成.
主要成果:
- 所有研究都表明,伊瓦布拉丁可以降低POTS患者的心率.
- 报告了包括改善身体和社会功能在内的症状益处.
- 报告的副作用包括胸,恶心和视觉障碍.
结论:
- 低质量的证据表明,伊瓦布拉丁可以降低心率并改善POTS症状.
- 需要进一步进行高质量的随机试验,以确定伊瓦布拉丁在POTS治疗中的作用.
相关概念视频
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
1.5K
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
1.5K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
1.4K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
1.4K
Dysrhythmias VI: Management of Dysrhythmias
414
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
414
Decreased pulse rate
824
Bradycardia is a medical condition in which the heart rate is slower than normal. It occurs when the heart's natural pacemaker, the sinus node, generates slower electrical impulses than the standard rhythm. In adults, bradycardia is diagnosed when the pulse rate falls below 60 beats per minute, indicating a deviation from the normal heart rate range.
There are specific risk factors that can elevate the likelihood of developing bradycardia. Advanced age is a significant factor, with...
There are specific risk factors that can elevate the likelihood of developing bradycardia. Advanced age is a significant factor, with...
824
Heart Failure Drugs: β-Blockers
737
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
737
Heart Failure Drugs: Inotropic Agents
1.2K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.2K


